Discover Our Purpose

Vision

Our Vision

To become a recognized and esteemed leader in the field of biotechnology, specializing in immunology. We aim to drive innovation in biologics and precision immune cell therapies, revolutionizing cancer treatment.

Mission

Our Mission

We are committed to fostering a culture of continuous research and collaboration with promising innovators and renowned scientists. Through these partnerships, we strive to discover and develop cutting-edge precision immuno-based treatments that address a wide range of illnesses and diseases, ultimately improving patients' lives.

Value

Our Values

At our core, we embrace the values of resilience, innovation, strength, integrity, and sustainability (RISIS). These values guide our every endeavor, empowering us to overcome challenges, push boundaries, maintain the highest ethical standards, and ensure the long-term viability and positive impact of our work.

Guiding the Path to Success

Our Leadership

Dr Lim Kah Meng

Founder

Experienced scientist in the biotechnology and biopharmaceutical industry
Started his career as a Research Scientist in A*Star and as a Professor in NTU before venturing as an entrepreneur and advisor to several biotech companies
Currently serving as Independent Director in a SGX listed company and Board director in several other biotech companies
Ph.D. in Biomedicine from National University of Singapore

Professor John Edward Connolly

Co-Founder

Chief Industry Officer and Research Director at the Institute of Molecular and Cell Biology at A*STAR
Chief Scientific Officer, Parker Institute for Cancer Immunotherapy
Pioneer of CAR-T Therapy work and former Scientific Advisor at Tessa Therapeutics
Ph.D. in Immunology from Dartmouth Medical School

Dr Poh Chit Lai

Chief Scientific Officer

Distinguished Professor, Head of the Centre for Virus and Vaccine Research at Sunway University
Editorial Committee of the Journal of Bioscience and Bioengineering, published by the Fermentation Society of Japan
Ph.D. in Science, majoring in Microbiology, Monash University (Australia)

Driving Advancements Together

Strategic Science Partners

Professor Nicholas RJ Gascoigne

Advisor

A renowned immunologist
Professor and former Head of Department of Microbiology and Immunology at the Yong Loo Lin School of Medicine, National University of Singapore
Postdoctoral Molecular Immunology from Stanford University School of Medicine
Philosophy (Ph.D.) Immunology from University College
London

Dr Leong Wai Fook

Partner, Scientific Affairs

Senior research fellow in Singapore Immunology Network, A-STAR
Council member in the Singapore Society for Microbiology and Biotechnology
Ph.D. in Microbiology (Virology) at the National University of Singapore

Yuta Lee

Partner, Technology Affairs

Founder & CEO of Accelerated Biosciences Corp, a Philadelphia-based
biotechnology company
President of ZMI Electronics Ltd., a Taiwanese company specializing in the research, development, and manufacture of medical devices
EMBA in Business from China Europe International Business School (CEIBS)

Our aim

The first and only scalable CAR Immune cell expansion company listed in the world

  • IMMUNOVEST has a patented donor blood cell-based CAR Immune cell expansion technolgy
  • IMMUNOVEST is the first and only company in the world to engage in a patented iPSC-based macrophage yδ NKT cell technology. This technology can be translated into bona fide “off-the-shelf” immunotherapeutics for a broad spectrum of cancers